An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease

Cancer

Volumn 95, Issue 12, 2002, Pages 2534-2538

  Chronowski, Gregory M ^a   Wilder, Richard B ^a   Tucker, Susan L ^a   Ha, Chul S ^a   Sarris, Andreas H ^a   Hagemeister, Fredrick B ^a   Barista, Ibrahim ^a   Hess, Mark A ^a   Cabanillas, Fernando ^a   Cox, James D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

2 microglobulin; Chemotherapy; Hodgkin disease; Prognosis; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; LOMUSTINE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIATION DOSE; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; LOMUSTINE; MALE; MECHLORETHAMINE; MIDDLE AGED; PREDNISONE; PROCARBAZINE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UP-REGULATION; VINBLASTINE; VINCRISTINE;

EID: 0037114737     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10998     Document Type: Article

References (32)

1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 1998;339: 1506-1514.
2. Franklin J, Paulus U, Lieberz, Breuer K, Tesch H, Diehl V. Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin's Lymphoma Study Group. Ann Oncol. 2000; 11:617-623.
3. Dimopoulos MA, Cabanillas F, Lee JJ, et al. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol. 1993;11:1108-1111.
4. Vlachaki MT, Ha CS, Hagemeister FB, et al. Long-term outcome of treatment for Ann Arbor stage I Hodgkin's disease: Patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys. 1997;39:609-616.
5. Liebenhaut MH, Hoppe RT, Efron B, Halpern J, Nelsen T, Rosenberg SA. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J Clin Oncol. 1989;7:81-91.
6. Specht L, Nissen NI. Prognostic significance of tumour burden in Hodgkin's disease PS I and II. Scand J Haematol. 1986;36:367-375.
7. Verger E, Easton D, Brada M, Duchesne G, Horwich A. Radiotherapy results in laparotomy-staged Hodgkin's disease. Clin Radiol. 1988;39:428-431.
8. Mauch P, Tarbell N, Weinstein H, et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol. 1988;6:1576-1583.
9. Colonna P, Jais JP, Desablens B, et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol. 1996;14:1928-1935.
10. Sarris AH, Kliche KO, Pethambaram P, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999;10:433-440.
11. Axdorph U, Sjoberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Bjorkholm M. Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease. Ann Oncol. 2000;11:1405-1411.
12. Christiansen I, Sundstrom C, Enblad G, Totterman TH. Soluble vascular cell adhesion molecule-1 (sVCAM-1) is an independent prognostic marker in Hodgkin's disease. Br J Haematol. 1998;102:701-709.
13. Nadali G, Tavecchia L, Zanolin E, et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome, Blood. 1998;91:3011-3016.
14. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971;31:1860-1861.
15. Lukes RJ, Gompel LF, Hall TC, Rappaport H, Ruben P. Report of the nomenclature committee. Rye classification. Cancer Res. 1966;26(Part 1):1311-1320.
16. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26:1063-1083.
17. Mauch P, Goodman R, Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer. 1978;42:1039-1045.
18. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989;73:47-56.
19. Hagemeister FB, Purugganan R, Fuller L, et al. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy. Semin Hematol. 1994;31(2 Suppl 3):36-43.
20. Tormo M, Terol MJ, Marugan I, Solano C, Benet I, Garcia-Conde J. Treatment of stage I and II Hodgkin's disease with NOVP (mitoxantrone, vincristine, vinblastine, prednisone) and radiotherapy. Leuk Lymphoma. 1999;34:137-142.
21. Fuller LM, Hagemeister FB, North LB, McLaughlin P, Velasquez WS, Cabanillas F. The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: Preliminary results. Int J Radiat Oncol Biol Phys. 1988;14:683-692.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1-39.
24. Grey HM, Kubo RT, Colon SM, et al. The small subunit of HL-A antigens is beta 2-microglobulin. J Exp Med. 1973;138: 1608-1612.
25. Cresswell P, Springer T, Strominger JL, Turner MJ, Grey HM, Kubo RT. Immunological identity of the small subunit of HL-A antigens and beta2- microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci USA. 1974;71:2123-2127.
26. Wibell L. The serum level and urinary excretion of beta2-microglobulin in health and renal disease. Pathol Biol (Paris). 1978;26:295-301.
27. Bataille R, Durie BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging. Br J Haematol. 1983;55:439-447.
28. Melillo L, Musto P, Tomasi P, et al. Serum beta 2-microglobulin in malignant lymphoproliferative disorders. Tumori. 1988;74:129-135.
29. Swan F Jr., Velasquez WS, Tucker S, et al. A new serologic staging system for large-cell lymphomas based on initial B2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989;7:1518-1527.
30. Litam P, Swan F, Cabanillas F, et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med. 1991;114:855-860.
31. Hagberg H, Killander A, Simonsson B. Serum beta 2-microglobulin in malignant lymphoma. Cancer. 1983;51:2220-2225.
32. Constantinides IP, Pathouli C, Karvountzis G, et al. Serum beta 2 microglobulin in malignant lymphoproliferative disorders. Cancer. 1985;55:2384-2389.